However, on the basis of our experimental data, we suggest that the control of TGF-β as a therapeutic intervention to blunt HTMC pathobiology and/or avoid the oxidative stress process may be a possible cause of the etiology and progression of HTMC pathobiology, probably improving increased IOP-mediated glaucoma. This evidence concerns the gene TGFB1 and glaucoma.